Floatz logo

FES F-18

Carcinoma, Lobular

Asan Medical CenterSmall moleculePhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Carcinoma, Lobular cohort.

Asset / SponsorPhaseRating
FULVESTRANT
M.D. Anderson Cancer Center
Phase 3BB
Arimidex
Alliance for Clinical Trials in Oncology
Phase 3B
Capecitabine
Auxilio Mutuo Cancer Center
Phase 2CCC
FAPI74
Randy Yeh
Phase 2CCC
FLUDEOXYGLUCOSE
Randy Yeh
Phase 2CCC

View all 21 →

Same molecule, other indications

FES F-18 is also rated in:

breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →